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ABSTRACT 
Dystrophia myotonica (DM1), one of the most common forms of muscular dystrophy, is caused by a 
repeated trinucleotide expansion in the DMPK gene.  This mutation results in the accumulation of toxic 
cellular RNA transcripts.  Spliceosome-mediated RNA trans-splicing (SMaRT) technology is a form of 
gene therapy that possesses the potential to correct these toxic RNA transcripts and thus cure the disease.  
Despite its promise, prior applications of SMaRT technology to DM1 have been hampered by poor 
efficiency and have not been validated in a relevant model of the disease.  In order to improve the 
efficiency of trans-splicing, this study examined the use of novel SMaRT molecules containing altered 
binding domains.   These SMaRT molecules were tested in a clinically relevant cell model of DM1 and 
their corrective ability compared to that of a standard SMaRT molecule. The results were quantified by 
RT-PCR.  The outcome of this study indicated the need to utilize more specific methods for measuring 
efficiency and for understanding the specific interactions of SMaRT molecules with target transcripts. 
INTRODUCTION  
1. DM1 overview 
The foundation set in the mid-20th century regarding the molecular basis of heredity resulted in a new 
perspective into disease etiology and pathology. With the completion of the human genome project and 
the systematic mapping of genes in the early parts of the 21st century, many disease states could, for the 
first time, be linked to genetic mutations.   The result was the re-categorization and diagnosis of disease 
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from a system based largely on symptoms and physical manifestations to one more closely defined by 
molecular signatures.     
1.1 Physical Characteristics associated with Dystrophia Myotonica Type 1 
Myotonic Dystrophy or dystrophia myotonica type 1 (DM1) stands as an archetypal example of a disease 
whose identity has been re-examined and redefined in the genetic era. DM1 ranks as one of the most 
common types of muscular dystrophy and is considered the highest overall contributor to adult muscular 
dystrophies.  It is estimated that as many as 20 in 100,000 people are affected by DM1 1 . The 
characteristics associated with the syndrome were first identified in the early 1900s by the German 
physician Hans Steinert2.  Because of his work, this type of muscular dystrophy was first referred to as 
“Steinert’s disease”.  Some of the prominent physical manifestations that are characteristic to DM1 
include muscle weakness and wasting, myotonia, cardiovascular disorders and cataracts3.   
 1.2 Genetic Description 
With the rise of genetic testing, a specific genetic anomaly was identified with DM1.  Through patient 
testing, it was found that the symptoms of DM1 were associated with an extended trinucleotide repeat 
(CTG) within the dystrophia myotonica protein kinase (DMPK) gene.  The repeat sequence is located 
within the 3’ untranslated region of exon 15.   This repeat sequence is present within all DMPK 
transcripts and within a phenotypically normal individual it contains up to 50 repeats4.  Through a 
process called repeat expansion, additional CTG repeats can be added during the replication preceding 
meiosis, allowing the repeat section to be increased.  The result is that in subsequent generations these 
repeats can accumulate causing the repeat expansion to become increasingly enlarged.   Individuals with 
fewer than 37 repeats are considered to be free from the risk of affected offspring5.  The expansion size 
can range anywhere from hundreds to thousands of repeats.  The severity of the disease, however, 
increases as the numbers of repeats increases.  Alleles containing more than 1000 repeats are responsible 
for the most severe form of the disease, congenital onset DM1, which carries an increased mortality 
rate6. Table 1 gives a succinct listing of the interaction between trinucleotide expansion length and 
disease expression patterns as defined by the NCBI7.   
                                                 
1 Johnson and Heatwole, 2012 
2 Steinberg and Wagner, 2008 
3 Ranum and Day, 2004 
4 Ibid. 
5 Foff et al, 2011 
6 Magana and Cisneros, 2011 
7 Bird, 1999 
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 DM1 is one of a number of diseases caused 
by nucleotide repeat expansions.  As part of 
this class of diseases, DM1 takes its place 
among spinocerebellar ataxias (SCA), 
fragile-x syndrome (FXS), Freidrich ataxia 
(FRDA), as well as Huntington disease 
(HD)9, 10 
2. Proposed toxicity mechanisms within DM1: A multi-faceted disease 
Knowing the particular genetic mutation associated with a disease state is only the beginning of a full 
understanding that could lead to practical cures.  Following the initial identification of the genetic 
mutation associated with DM1, much of the research focused on nucleotide repeat disorders has 
involved determining the molecular mechanisms that lead to the symptoms observed in the disease state.  
DM1 has proved to be one of the prime models used to study the mechanisms of toxicity of genes bearing 
expanded repeats.  Though some pieces are coming together, the full picture of the mechanisms of 
pathogenesis of DM1 still remains muddled and inexact.  In the quest to discover what is occurring 
within the cells containing the extended repeat, many mechanisms have been hypothesized and 
investigated.    
2.1 Protein Toxicity 
Although DMPK expression by the expended repeat may not be affected, the portion of the 3’ 
untranslated region of the DMPK gene which contains the CTG repeats is overlapped by the promoter 
for another gene, the sine oculis related homeobox 5 (SIX5) gene11. Within cells that contain mutant 
DMPK genes, there is an indication that SIX5 transcription is impaired.  As evidence of this, knockout 
murine models displayed the occurrence of ocular cataracts, a characteristic of DM1.  Because of this 
result, it is thought that loss of SIX5 may play a role in part of the observable symptoms associated with 
the disease12.   
Recent studies have also identified the potential for the production of a harmful protein product from 
the extended repeat sequence through a mechanism called Repeat Associated Non-ATG translation 
                                                 
8 Bird, 1999 
9 Sicot and Gomes-Pereira, 2013 
10 Nalavade et al, 2013  
11 Sicot and Gomes-Pereira, 2013 
12 Belizil et al, 2013 
Table 1: CTG repeat length and DM1 expression8 
(CUG)n 
Repeat Size (n) Classification Age of Onset 
35 - 49 Normal N/A 
50 - ~150 Mild DM1 20-70 years 
~100 - ~ 1000 Classic DM1 10-30 years 
> 1000 Congenital Birth-10 years 
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(RAN translation)13. Within expanded CAG sequences, translation has been found to occur through non-
ATG-initiation mechanisms.  Though the DMPK gene is transcribed in the sense direction, the 
occurrence of bidirectional transcription has been observed in similar expanded trinucleotide repeat 
diseases such as Huntington disease-like 2 (HDL2), spinocerebellar ataxia type 8 (SCA8), and fragile-
x ataxia syndrome (FXTAS)14.  This bidirectional transcription within mutant DMPK genes would result 
in transcripts comprised of elongated CAG and CUG sequences capable of RAN translation.  When 
RAN occurs in DM1 transcripts, the reading frame is arranged in all three windows on both transcripts, 
resulting in five different theoretical long homomeric protein chains: polyglutamine, polyserine, 
polyalanine, polyleucine, and polycysteine15.  Within murine neuroblastoma cells, it was found that the 
presence of these long homomeric protein chains was associated with cellular apoptosis16.  This newly 
investigated mechanism holds much potential in understanding the molecular pathogenesis of DM1 and 
may be an important cause of DM1 symptoms.   
2.2 RNA Toxicity  
The main focus of DM1 toxicity, however, has been on the role of the mutant RNA transcripts within 
the disease pathway.  The idea of RNA toxicity is based on RNA-gain of function.  Gain of function 
occurs when any molecule assumes a mechanism or action that it does not normally perform.   Mutant 
RNA is particularly susceptible to picking up new functions due to its ability to form diverse secondary 
structures and its known place in cellular regulation.  The precise processes of RNA pathogenesis are 
areas of much intense research, but three prime mechanisms of RNA sabotage have come into focus: 
the sequestration of MBNL1, the foci formation of the MBNL1 and mutant DMPK complex, and the 
overexpression of CUGBP1. 
 MBNL1 is a member of the musclebind family of proteins and is responsible for the regulation of 
alternative splicing of specific genes, including the pre-mRNA of the chloride channel (CLCN1), insulin 
receptor (IR) and cardiac troponin-T (TNNT2) genes.17, 18 The presence of extended CTG repeat results 
in the binding of the MBNL1 to the mutant DMPK RNA19, which recognizes the double stranded hairpin 
structures formed by the CUG repeats20.  The MBNL1 and mutant DMPK complex is proposed to affect 
the cell in two ways.   The first and simplest consequence comes from the loss of function of MBNL1.  
                                                 
13 Belizil et al, 2013 
14 Rnoux andTodd, 2012  
15 Belizil et al, 2013  
16 Zu et al, 2011  
17 Nelson et al, 2013 
18 Nalavade et al, 2013 
19 Ibid. 
20 Cho and Tapscott, 2007 
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Because of the exclusive binding that occurs between MBNL1 and the mutant DMPK, it is proposed 
that this sequestration results in MBNL1 being unavailable for the regulation of splicing for which it is 
responsible21.  With the mutant DMPK-induced loss of function of MBNL1, a high rate of aberrant 
splicing is observed among cellular transcripts, many of which are linked directly to phenotypic 
manifestations of DM122.   As evidence of this, transgenic mice containing non-binding MBNL1, display 
abnormalities and defects that are consistent with those observed in DM1, in particular, the occurrence 
of myotonia, ocular cataracts and aberrant splicing patterns23.    
CUGBP is another important RNA binding that has been implicated in the molecular pathogenesis of 
DM1.  Like MBNL1, CUGBP is integral to splicing pattern determination and the two proteins work in 
concert to regulate splicing patterns24.  CUGBP has also been identified as being important in mediating 
mRNA decay and increasing translation of proteins such as p2125,26.  When MBNL1 concentrations are 
disturbed by the formation of the mutant DMPK-MBNL1 complex and its segregation to the nucleus, 
CUGBP levels are increased.  The abnormal ratio of these two proteins with DM1 cells is similar to that 
in the embryonic state27.   
The loss of MBNL1 and CUGBP1 function has been shown to be only a partial contributor to DM1 
pathogenesis. Studies point to the MBNL1 and mutant DMPK complexes being integral to the 
development of the DM1 phenotype.  Within DM1 cells, the MBNL1-mutant DMPK complexes form 
foci which are localized in the nucleus.  Though healthy cells do not typically display these foci, it was 
found that the position of these complexes in the nucleus rather than in the cytoplasm was key to DM1 
toxicity.  Why cytoplasmic foci would not display the same toxicity as nuclear foci is not known, but it 
gives an important indication that part of the toxicity caused by these complexes must involve 
interference with the normal processes of the nucleus28, 29.  It should also be noted that both CAG and 
CUG repeats have been found to equally contribute in foci formation30.  These foci are increasingly 
becoming the most strongly associated mechanism with the pathogenesis of DM1.  A summary of 
proposed mechanisms can be seen in table 2.  
                                                 
21 Sicot and Gomes-Pereira, 2013 
22 Renoux and Todd, 2012 
23 Kanadia et al, 2003 
24 Ward et al, 2005 
25 Vlasova et al 2008 
26 Timchenko et al, 2004 
27 Sicot and Gomes-Pereira, 2013 
28 Mankodi et al, 2001 
29 Taneja et al 1995 
30 Ho et all, 2005  
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Table 2: Proposed Mechanisms of Toxicity within DM1 
Protein 
Type Category Description Result 
DM1 
Phenotypes 
Associated 
Sources 
DMPK 
protein loss 
Loss of 
function 
Mutant DMPK 
transcripts interfere 
with normal 
translation 
processes 
Decreased levels of 
DMPK protein 
Late onset 
myopathy; 
delays in 
cardiac 
conduction 
Jansen, et 
al, 2003; 
Berul et al, 
1998 
RAN 
translation 
Gain of 
function 
Random non ATG 
initiated translation 
occurs 
 
Homopolymeric 
polyglutamine, 
polyalanine and 
polyserine proteins 
created which can 
interfere with 
cellular processes 
 
Still under 
investigation 
Cleary, 
Ranum, 
2014; Zu et 
al 2010 
SIX5 gene 
expression 
disruption 
Decreased 
expression 
Overlap of DMPK 
UTR with promoter 
of SIX5 gene 
 
Extended repeats in 
DMPK may inhibit 
or limit expression 
of the SIX5 protein 
 
Ocular 
cataracts 
Flippova, 
et al, 2001 
RNA 
MBNL1 
sequestration 
Loss of 
function 
MBNL1 associates 
with extended 
repeat portion of 
mutant DMPK 
 
Binding of MBNL1 
to DMPK transcripts 
results in MBNL1 
not being available 
for splicing 
regulation of normal 
target proteins 
 
Myotonia, 
ocular 
cataracts, 
cardiac 
conduction 
defects 
Sicot et al, 
2013; 
Kanadia et 
al, 2003 
MBNL1-
DMPK 
nuclear foci 
formation 
Gain of 
Function/inter
ruption of 
baseline  
 
MBNL1 complexes 
with mutant DMPK 
and forms foci 
within nucleus 
 
Foci seem to be 
toxic when located 
within the nucleus 
Still under 
investigation 
Mankodi et 
al, 2001; 
Taneja et 
al, 1995 
CUGBP1  
(CELF) 
upregulation 
Over-
expression 
CELF expression 
associated with 
MBNL1, loss of 
MBNL1 results in 
increased 
expression of 
CUGBP 
Missplicing of 
targeted transcripts 
including Tnnt2, 
Mtmr, Clcn1; return 
to fetal splicing 
patterns; 
Insulin resistance 
Myotonia, 
muscle 
wasting, 
DM1 
histopathy, 
Ho et al, 
2005; Ward 
et al, 2010; 
Timchenko 
et al, 2001; 
Philips et 
al, 1998 
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3. Methods of Repair of DM1 
The understanding of disease processes is driven by the quest to find methods of alleviation and 
treatment.  Increased genetic classification and identification of diseases has given rise to new forms of 
treatment.  Targeting molecular sources of disease is all part of the increasingly prominent field of gene 
therapy.  Traditional gene therapy approaches have mainly focused on introducing complete genes in 
order to restore proper protein levels within a system.  Though this aspect may relieve some symptoms, 
the previous discussion on mechanisms of disease shows that in a DM1 individual the main pathogenesis 
is due to the presence of mutant DMPK RNA.  Because of this, molecular therapeutic treatments for 
DM1 must include targeting of these toxic RNA transcripts.   Ideally, molecular therapy for correction 
of DM1 would fulfill all of the following requirements.  1) Therapy mechanism would be specific to 
mutant DMPK transcripts only.  2) Therapy molecules would be small enough to effectively administer.  
3) Therapy would retain the normal transcription levels dictated by the cell and would not interfere with 
cellular control mechanisms.    
Several strategies of targeting extended repeat DMPK transcripts have been proposed to treat DM1.  The 
use of small interfering RNA (siRNA) has been proposed and tested as a possible mechanism for mutant 
DMPK RNA repair.  SiRNA are small double stranded RNA molecules homologous to an intended 
target.  These molecules have been shown to bind to target RNA and induce post transcriptional 
silencing through targeting of mRNA for degradation by endogenous enzymes.  Within a DM1 model, 
siRNA modified for nuclear localization were shown to successfully degrade nuclear and cytoplasmic 
DMPK transcripts. The difficulty arising from this method of DM1 alleviation, however, was the failure 
of the mechanism to distinguish between the mutant and wild-type DMPK transcripts31.  Additionally, 
the destruction of DMPK transcripts that occurs in this therapy greatly alters the steady cellular levels 
of DMPK protein being translated, an event which usually has severe consequences to the cell. 
A more promising method is to be found in the family of antisense oligonucleotides (AONs).   Two 
leading classes of these AONs have been used with DM1, 2’O-methyl-modified AONs (MOEs) and 
phosphodiamidate morpholino antisense molecules (PMOs or morpholinos)32.  Similar to the use of 
siRNA, AONs work by post transcriptional gene silencing, either by targeted degradation or by steric 
interference induced inhibition.  Certain MOEs have been tested within a DM1 cell model, and it was 
found that this therapy model appeared to effectively degrade and reduce the number of mutant DMPK 
mRNA within both the cytoplasm and the nucleus.  In vivo trials showed up to 80% silencing of the 
                                                 
31 Langlois, et al, 2005  J. Biological Chemistry 
32 Pennock et al, 2011 
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expanded repeat DMPK transcripts33.  A study has also shown morpholinos successful in disrupting the 
mutant DMPK mRNA and MBNL1 foci within the nucleus. There was also some indication that the 
morpholinos might increase the degradation of these transcripts34.  In both cases, however design of 
these AONs was only theorized to be specific to extended CUG repeats.   Whether normal DMPK 
transcripts were also affected was not thoroughly evaluated, though in general the specificity of 
morpholinos has been shown to be fairly high35.  Though the use of AONs holds the possibility of 
disrupting the toxic DMPK foci, as with the previously discussed RNA interference pathways, these 
therapies fall short of the ideal in their inability to retain the normal DMPK expression patterns that 
occur when both DMPK alleles are producing functional mRNA.   
Answering the call of this short-coming, a new area of gene therapy has risen and begun to take its place: 
mRNA repair through the use of trans-splicing.   Eukaryotic mRNAs require post-transcriptional 
modification which includes the splicing together of exons and the removal of introns.  The splicing 
normally observed in this stage is referred to as cis splicing, and occurs within a single linear pre-mRNA 
molecule.  The arrangement of exons and 
exclusion of different areas of the molecule is 
in part responsible for the great variation seen 
in eukaryotic organisms.  Trans-splicing 
works similarly, however, the splicing in this 
instance is no longer within the same 
molecule, but occurs between two different 
pieces of RNA.  Figure 1 gives a visual 
example of the difference between the two 
methods of splicing.   
As can be seen in the figure, trans-splicing allows the substitution of another portion of RNA within a 
modified mRNA transcript.  The application to genetic therapy is readily apparent.  Different from the 
methods previously mentioned, trans-splicing could potentially repair mutant transcripts prior to 
translation and without modification or alteration of the promotion or transcription of the gene.  Within 
DM1, trans-splicing would allow the mutant exon 15, containing the extended trinucleotide repeat, to 
be replaced with a normal exon 15, containing fewer than 50 repeats. 
                                                 
33 Mulders et al, 2009 
34 Wheeler et al, 2009 
35 Pennock et al, 2011 
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The therapeutic use of trans-splicing was first explored with the use of ribozyme-mediated trans-
splicing.  This type of trans-splicing repair makes use of a synthetically arranged sequence containing 
both a binding domain for locating of the target RNA, and the exonic sequences to be spliced.  In order 
for splicing to occur within this model, however, a RNA catalyst, or ribozyme must also be included 
within the therapeutic molecule.  Past studies have examined the repair characteristics of this method of 
therapy in several disorders including their repair efficiency in DM1 fibroblast cells36.  Though repair 
has been observed using such mechanisms, ribozyme mediated trans-splicing has several shortcomings 
which prevent its progression to a clinically relevant therapy option.  The most prominent of these are 
linked to the necessary inclusion of the ribozyme.  The main difficulty faced with this approach was the 
inefficiency of the included ribozyme within physiological Mg+ concentrations37.   
In 1992, it was discovered that mammalian cells possessed the endogenous machinery necessary for 
performing trans-splicing38.  This revelation opened a new opportunity for the use of trans-splicing.  
Within the mammalian cell, the enzyme responsible for splicing is the spliceosome.  Based on the 
finding that eukaryotic spliceosomes were capable of performing trans-splicing as well as the usually 
observed cis-splicing, a novel method of RNA repair was introduced: spliceosome mediated trans-
splicing (SMaRT).  Since all eukaryotic cells contain the spliceosome needed for SMaRT technology, 
the need to supply machinery such as ribozymes for initiating the splicing event was obviated.  Since 
the strongest setbacks in feasibility of use of trans-splicing for therapy were due to presence of the 
ribozymes, SMaRT has become a much more promising type of RNA repair.   
Since its introduction, the mRNA repair capabilities of SMaRT therapy have been examined in a 
growing number of genetic disorders.  Artificial trans-splicing has been conducted in disease models of 
hypertrophic cardiomyopathy 39 , Huntington’s disease (HD) 40 , epidermolysis bullosa simplex with 
muscular dystrophy (EBS-MD)41, and hemophilia A42.   This type of trans-splicing was also used within 
the context of DM1 by Chen et al in 2009.  Most of these studies have served as proof of concept for 
SMaRT mRNA repair.   
The translational potential of SMaRT technology is difficult to judge due to several reasons.  One reason 
is due to the wide variability in efficiency measurements which prevents direct comparison.  Several in 
                                                 
36 Phylactou, et al, 1998 
37 Wood, et al 2007 
38 Bruzik and Maniatis, 1992 
39 Mearini et al, 2013 
40 Rindt 2012 
41 Wally et al, 2007 
42 Chao et al, 2003 
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vitro experiments have reported trans-splicing efficiency between 1-14%.  In vivo studies, however, the 
efficiency has been found between 3-7%43.  In a study where SMaRT was applied directly to DM1, the 
efficiency of repair was 1.8-7.41%44.  
Additionally, the differences in disease models also effects the conclusions as to the efficiency of the 
SMaRT therapy.  Many of the disease models used thus far have been made by the use of artificial 
constructs, where the desired target of repair is found within an extra-chromosomal plasmid.  For some 
of the genetic mutations, such as HD and EBS-MD, the trans-splicing evaluation of the PTMs was also 
evaluated within patient-derived cell lines endogenously containing the mutated alleles4546. In general, 
the trans-splicing efficiency was greatly decreased within most of the more clinically relevant 
conditions. The efficiency of splicing repair in these studies was much less than in the artificial 
constructs.   
Despite the diversity of these studies, a common theme has been emphasized: the need for more 
efficiency and specificity of the splicing events.  For diseases where loss of protein is the main influence 
in disease prognosis, small levels of trans-splicing repair may be sufficient to alleviate symptoms.  
Because if this, PTMs with low splicing efficiency may be satisfactory.  It is important to note however, 
that low levels of trans-splicing repair may be enough to alleviate the disease state.  Even with the low 
efficiency of current SMaRT technology, research using murine disease models have shown the 
technology capable of causing significant phenotypic changes in hemophilia A and hypertrophic 
cardiomyopathy4748.  
For DM1, however, the presence of mutant mRNA is the main source of toxicity.  It is not known how 
many mutated DMPK transcripts are required for toxicity to occur.  Thus it can be assumed that DM1 
will require much higher trans-splining efficiency due to the RNA toxicity nature of the disease.  Before 
SMaRT can become a feasible clinical therapy option for patients suffering from DM1, it is imperative 
that the splicing efficiency of the therapeutic PTMs be improved.   Additionally, a clinically relevant 
model of DM1 has not yet been used to evaluate SMaRT technology.  Since the efficiency of trans-
splicing is not adequately reflected in artificial disease constructs, any improvement in efficiency must 
be evaluated within a model that reflects the complexity of the actual disease state.   
                                                 
43 Mansfield et al, 2004 
44 Chen et al, 2009 
45 Rindt, 2012 
46 Wally et al 2007 
47 Chao et al 2003 
48 Mearini et al, 2013 
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4. Experimental Details 
The purpose of this study was to improve PTM efficiency and specificity and to examine the trans-
splicing repair of PTMs using a patient-derived DM1 cell.  Because SMaRT technology relies on 
endogenous cellular mechanisms for splicing, the key to improving trans-splicing efficiency is to 
improve the PTM design so that it can be correctly identified by the cell and positioned near the desired 
target transcript.  Understanding how to improve PTM efficiency requires knowledge of PTM design as 
well as an understanding of how genetic material is naturally positioned and associated within the 
nucleus.  
4.1 Experimental Theory 
Basic PTMs are comprised of 
several specific sequences that 
fall into three main categories 
based on their function: the 
binding domain, the splicing 
domain, and the coding domain49.  
Each serves an important function 
within the cell and are visually 
represented in figure 2.   
 
The coding domain contains the portion of RNA that is to be incorporated into the target transcript.  The 
splicing domain consists of several unique features, most importantly, the pyrimidine-rich tract, the 
3’splice site and the branch point.  These are all features which allow the spliceosome machinery to 
identify this molecule as a splicing candidate and to correctly associate with it.  Typically, the splicing 
domain portions of the PTM are analogous to the splicing factors that would be found within an 
endogenous intron.   The final sequence of interest is the binding domain.  The purpose of the binding 
domain is to provide a sequence which will cause the cell to position the PTM near its target gene.  
Because splicing occurs co-transcriptionally, it is necessary that the PTM be located near to the actively 
transcribed target gene. It is this portion which largely determines the molecule’s specificity and 
efficiency.   The best PTM design is one which contains a binding domain that has learned to speak the 
language of nuclear positioning and sends a clear address of destination.   
                                                 
49 Mansfield et al, 2004 
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Since the goal is to localize the PTM to the position in the nucleus where transcription of the desired 
target is occurring, an understanding of nuclear organization is necessary.  The idea that the nucleus is 
a random network of genes and proteins has long been refuted and it is now known that the structure of 
its interior is highly complex.  Where genetic material is positioned within the nuclear matter is closely 
linked to the regulation of gene expression.   It has been found that within the nucleus, transcription 
tends to occur within foci, or in distinct groupings commonly referred to as transcription factories.  These 
transcription factories contain several genes which are actively transcribed by RNA polymerase II50.  
What is of importance is how the grouping of genes are determined within the factories. To date, this 
area currently under investigation, however it has been shown that homology of genes is a strong 
influence in the grouping seen in these foci51.  This concept was promoted by the finding that when a 
plasmid containing a β-globin gene was introduced to a mammalian cell, the nuclear machinery 
colocalized the plasmid with the homologous endogenous gene52.  Other studies have indicated that the 
promoter region of the gene may be the sequence responsible for inclusion in the transcription factory, 
that is, that homologous promoters are sequestered into the nuclear foci53.  
In order for a PTM to be efficiently transcribed and trans-spliced into the correct target, it must be 
located within the same transcription factory as the gene of interest.  Traditionally, the binding domain 
of PTMs has consisted of a sequence that is antisense to an intronic portion of the targeted pre-mRNA.  
This design is founded on the idea that the main stimulus in nuclear positioning is canonical Watson-
Crick base pair complementarity.  The recent investigations into the organization of the nucleus and the 
transcription factories cited above challenge this assumption. Based on the previously stated study 
regarding plasmid positioning within the genome, there is strong evidence that homology rather than 
complementarity may provide the strongest nuclear positioning “address”.   Because of this it is 
proposed that using a PTM containing a binding domain homologous to the target will increase the 
efficiency of trans-splicing.   
Experimental Design  
In this experiment, PTMs containing binding domains which were homologous to intron 14 of the 
DMPK gene were created.  The efficiency of these molecules was compared with that of PTMs 
containing the traditional antisense binding domain.  The efficiency of the two was evaluated by the use 
of two control PTMs.  For each of the experimental PTM types, controls were created by alteration of 
                                                 
50 Chakalva and Fraser, 2010 
51 Binnie et al, 2006 
52 Ashe et al,  1997 
53 Larkin et al, 2013 
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the 3’ splice site needed for recognition of the spliceosome. Figure 3 shows the four experimental PTMs 
created for the experiment.  An overall control was also used where no PTM was added to the cell 
culture.      
The model used for this 
experiment was a GM23300 
lymphocyte cell line derived 
from a patient suffering from 
DM1 and acquired from Coriell 
repositories.  This cell line 
contained both a mutant DMPK 
allele with around 150 to 160 
CTG repeats present in the 
mutant gene as well as normal allele.  The large difference in size between the wild type and the toxic 
DMPK transcript allows the two to be separated by size.  Thus, when run on a gel, a sample containing 
both types of transcripts would be expected to show a high band around 990 bp and a low band around 
500 bp.   
Evaluation of the presence of mutant DMPK transcripts by band density was the method employed for 
this experiment.  The density of the high band within the gel indicates the amount of toxic transcripts.   
Because a normal wild-type transcript is already present within the cell, the low band contains both 
trans-spliced correct DMPK mRNA as well as the normal transcripts derived from the endogenous wild-
type allele and prevents the direct determination of repaired transcripts.  However, as the efficiency of 
PTMs increases, the density of the high band should decrease and the low band increase.  Using this 
ratio of the two bands, the efficiency of the PTMs of interest can still be determined.  To standardize the 
expression levels between samples the amount of the housekeeping gene GAPDH was quantified.  
 
METHODS AND MATERIALS 
1. Designing PTMs 
1.1 Replication of normal intron 14 and exon 15 
A cell line containing two normal DMPK alleles (<50 CTG repeats) was used to isolate the coding 
domain for the PTMs.  The DNA from these cells was gathered using DNeasy DNA extraction kit from 
Qiagen.  PCR was performed with the extracted DNA as template using forward and reverse PCR 
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Primers, DMPK P1 and DMPK P2.  These primers were designed to amplify the portion of the gene 
containing intron 14 and exon 15.   Table 3 provides a tabulated compilation of all primers used in the 
experiment. An inserted CACC sequence was added at the beginning of the forward primer, DMPK P1 
to allow for insertion into the TOPO vector.  AcuPrime GC Rich DNA polymerase was used due to the 
high CG content of the desired sequence. 
The PCR reaction was performed using 200 ng of template DNA.  The resulting product was run on a 
0.5% agarose gel alongside a 1 kb ladder.  A visible band appeared within the range of the expected size 
for the PCR product, which was approximately 1356 bp.  The portion of the gel containing this product 
was excised and the genetic material removed from the agarose with a gel extraction kit.     
1.2 Creation of sense PTM plasmids: pc3.3 DMPK 
Using the pc.DNA3.1 Directional TOPO Expression kit from Invitrogen, the PCR product was ligated 
into the backbone according to the manufacturer’s protocol.  These plasmids were introduced into 
chemically competent TOP10 bacterial cells via heat shock, plated on a pre-warmed plate containing 
ampicillin and allowed to grow overnight.  It was observed that the growth of these colonies was much 
slower than to be expected.  
Three colonies were chosen from the plate and the plasmids were extracted using Qiagen’s MiniPrep 
kit.  To confirm the presence of the DMPK portion within the cellular plasmids, the collected genetic 
product from the three cell lines were treated 
with Nde I and XhoI restriction enzymes.  After 
separating the fragments by gel electrophoresis, 
the second sample was the only one to show a 
band within the proper range for the desired 
product.  This clone was submitted for 
sequencing which confirmed that the topo 
plasmid contained the amplified intron 14 and 
exon 15. 
Further modifications were made to the inserted 
DMPK portion.  Using site directed mutagenesis the 5’ GT splice site was removed to prevent any cis-
splicing from occurring within the molecule. An EcoRI site was also added just upstream of exon 15.  
An image of the modified pcDNA plasmid can be seen in figure 4.  
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1.3 Creation of anti-sense binding domain PTM: pc 3.3 DMPK AS 
To create an anti-sense sequence, the binding domain was amplified by PCR using primers DMPKin14 
P1 and 2.  These were designed to introduce a KpnI restriction site at the end of the binding domain of 
intron 14 and an EcoRI restriction site upstream of the donor splice site.  Sense PTM plasmids and the 
purified PCR product from this step were both digested with KpnI and EcoRI and then ligated together.  
Because of the location of the KpnI and EcoRI within the vector, this step reversed the orientation of 
the binding domain portion, resulting in the desired anti-sense PTM.   
1.4 Creation of control PTM plasmids: pc3.3 DMPK 3’ss and DMPK AS 3’ss 
Controls were created for both the DMPK and DMPK AS PTMs by alteration of the AG 3’ acceptor 
splice site.  Through site directed mutagenesis, the AG splice site within intron 14 was replaced with a 
theoretically, inoperable AC sequence.  This step was performed by the use of primers DMPK 3ss_for 
and 3ss_rev.   
 
2. Optimization of analysis conditions 
2.1. Optimization of PCR reaction 
The GM23300 cell-line was the model used for this experiment. Prior to any experimentation, the 
baseline parameters of the experimental conditions were determined by optimization of RNA extraction, 
RT-PCR and electrophoresis conditions.   
Table 3: PCR Primers 
 
 Sequence (5’ 3’) 
 Forward Reverse 
DMPK P1 CACCTACGTCCGGCCCAG G  
DMPK P2  TAGCTCCCAGACCTTCG 
 
DMPK3ss_for CGCCCTCTCCCGCACGTCCCTA
GGC 
 
DMPK3ss_rev  GCCAGGCCTAGGGACGTGCGGGGAG 
 
DMPKin14 P1 AACTTGGTACCCCCGGCATGG
GCCT 
 
DMPKin14 P2  TCAACAGAATTCGAGCTCGGATCCAGT 
 
DMPK RT 3 CGGATCCTTCCCATCTA  
DMPK RT 4  CTGGCCGAAAGAAAGAAATG 
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Total mRNA from the DM1 cells was extracted using RNeasy mini kit from Qiagen.  This mRNA 
product was subjected to RT-PCR with using primers DMPK RT P3 and P4.  These primers were 
specialized to amplify the portions of transcript that included both the exon 14-15 junction and the 
(CTG)n repeat in Exon 15.  Transcripts from the mutant allele were expected to be around 884-914 base 
pairs with the normal allele expressing mRNA of only 494 bp in length.  These two transcripts were 
visibly distinguishable when run on a 0.5% agarose gel.   
Initially, some trouble was met in the PCR reaction particularly in the amplification of the mutant DMPK 
transcripts due to the high GC content. This difficulty was removed by the use of 5% DMSO in the PCR 
reaction mixture.  The resulting optimized PCR mixture and conditions for the DMPK replication is 
listed in Table 4.   GAPDH was used as the housekeeping gene. The PCR reaction analysis of this 
product was also adjusted prior to experimentation. Table 5 gives the subsequent settings for RT-PCR 
of GAPDH.  It should be noted that DMSO was not needed for the GAPDH analysis.   
2.2 Optimization of Electrophoresis 
The DMPK was found to separate best when run on a 1% agarose gel for an hour and 20 minutes.  
GAPDH, however, only required the length of an hour for electrophoresis.  These conditions were kept 
standard throughout the experiment.     
 
 3. PTM efficiency experiment 
3.1 Lipofectamine transfection  of PTMs into DM1 cell line  
The GM233300   cells were thawed and allowed to grow in RPMI media supplemented with 15% FBS 
and 1% penicillin-streptomycin.  Cell density was determined by hemocytometer-based counting and 
the culture was resuspended at a concentration of 1.2x106 cells per milliliter.   
Cells were plated in a 24 well plate. Each well was seeded with 0.5 milliliters of the DM1 cell culture.  
Five different conditions were analyzed in triplicate.  Two experimental PTMs were used, DMPK and 
DMPK AS, alongside the two control PTMs, DMPK Δ3’ss and DMPK AS Δ3’ss and the final condition 
contained no PTM.  Since each of the four PTM solutions had differing levels of genetic material, serum 
free medium was added individually to bring the concentration of each to 1.2 micrograms of DNA per 
50 microliters. Following the protocol for lipofectamine transfection, the lipofectamine was diluted with 
medium and combined with each of the PTM solution in a 50:50 ratio.  After allowing this mixture to 
incubate, 100 microliters of each lipofectamine and PTM solution were added to each well, respective 
of their identity.  Cells were then incubated for 24 hours at 37 C.   
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3.2 RNA extraction and PCR assembly 
Following incubation, the cells in each well were removed.  After pelleting by centrifugation, the cells 
were lysed using QIAshredder and RNA extracted using RNeasy mini kit.  The extracted RNA was 
spectroscopically quantified to determine concentration.   
Two RT PCR reactions were assembled for each of the reactions: one using DMPK primers and the 
other GAPDH primers.  The PCR reactions were mixed and run according to the optimized conditions 
listed in Table 4 for the DMPK reaction and Table 5 for the GAPDH reaction.  Because of the varying 
concentrations of base RNA, the volume added of each was determined so that a total of 100 nanograms 
of RNA was added to each reaction.  The difference in volume for each was compensated by the addition 
of sterile water. 
 
 
 
Table 4: RT-PCR DMPK Conditions 
5% DMSO Reaction 
 
PCR DMPK Schedule 
  
 Quantity (λ)  Time  
2x Reaction Mixture 25 55 C 30 minutes  
DMPK RT P3 1 94 C 2 minutes 
DMPK RT P4 1 94 C 15 seconds 
Repeat 39x SIII RT  2 62.9 C 15 seconds 
DMSO  2.5 68 C 75 seconds 
RNA Volume= 100ng 68 C 5 minutes  
PCR H2O Adjusted to bring 
total volume to 50 λ 
4 C ∞ 
Total  50    
Table 5: RT-PCR GAPDH Conditions 
Reaction 
 
PCR DMPK Schedule 
  
 Quantity (λ)  Time  
2x Reaction Mixture 25 55 C 30 minutes  
GAPDH rev 1 94 C 2 minutes 
GAPDH for 1 94 C 15 seconds 
Repeat 39x SIII RT  2 53.6 C 15 seconds 
RNA Volume= 100ng 68 C 75 seconds 
PCR H2O Adjusted to bring 
total volume to 50 λ 
68 C 5 minutes  
Total  50 4 C ∞ 
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3.3 RNA Analysis 
The resulting PCR products were run on the standard 1% agarose gel for the times determined in 2.2.  
The samples were run alongside a 100 bp ladder in a 16 well gel.  Using GeneSys software, the densities 
of each of the bands was determined and each normalized with the results of the GAPDH expression 
gel.  The ratios between the mutant and the normal DMPK transcripts were compared.  The efficiency, 
that is, the ratio of normal transcripts to mutant, of each PTM was compared with each other and with 
the controls.  Figure 6 contains the results of the DMPK gel and the numerical values for each can be 
found in table 4.   
RESULTS  
The gel results showing the mRNA DMPK products for each sample can be seen in Figure 5.  From this 
gel it can be seen that all the samples displayed a distinct high band and low band corresponding to 
mutant DMPK mRNA and wild type/corrected DMPK mRNA as expected.   The empty control samples 
seemed to show a much less distinct wild type sized product.  Table 6, however gives the numerical 
results for densities as determined by GeneSys.  Figure 6 gives ratio of densities of the high band over 
the low band, that is, the number of mutant transcripts per normal transcripts for each experimental 
condition after each was standardized by GAPDH expression. 
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Table 6: Results- DMPK RT-PCR product band density evaluation 
 DMPK GAPDH 
 
DMPK/GAPDH 
Hi/Lo Average 
Standard 
Deviation 
 ~1100bp ~500 bp 
 
 
 Hi 
(Mutant) 
Lo 
(correct) 
Hi Lo 
 
1.1 218.1097 146.62 992.3121  0.219799 0.147756 1.487585 
1.207181 0.253095 1.2 142.5281 125.2107 1093.682  0.13032 0.114485 1.138306 
1.3 166.5916 167.3189 1116.483  0.149211 0.149862 0.995653 
 
2.1 112.2278 154.0862 170.0726  0.659882 0.906002 0.728344 
1.286695 0.771907 2.2 211.6267 97.63383 1345.464  0.157289 0.072565 2.167555 
2.3 139.2424 144.4144 1273.33  0.109353 0.113415 0.964186 
 
3.1 139.653 62.85316 1257.736  0.111035 0.049973 2.221893 
1.551194 0.596997 3.2 183.4277 135.4922 1157.47  0.158473 0.117059 1.353788 
3.3 104.6203 97.05919 1877.922  0.055711 0.051684 1.077902 
 
4.1 323.1386 91.56604 1162.54  0.277959 0.078764 3.529022 
2.803667 0.879389 4.2 127.285 69.72279 1119.243  0.113724 0.062295 1.825587 
4.3 227.469 74.42402 1075.686  0.211464 0.069187 3.056392 
 
5.1 44.55943 17.83333 1004.617  0.044355 0.017751 2.49866 
6.07808 4.021466 5.2 306.2594 57.71995 914.3212  0.334958 0.063129 5.305954 
5.3 196.0608 18.79845 837.5276  0.234095 0.022445 10.42963 
Key:    1) DMPK     2) DMPK AS    3) DMPK Δ3’ss     4) DMPK AS Δ3’ss     5) Control 
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DISCUSSION 
A visual analysis of the results as seen in figure 6 may at first glance present a confusing picture.  
Initially, it gives the indication that the ratio of mutant to normal transcripts was greater in the overall 
control, and that the presence of PTMs regardless of their splicing capabilities seemed to decrease the 
amount of toxic transcripts. The wide error bars seen in the graph, however, give an indication that the 
numerical results might be lacking in significance   ANOVA and post hoc test analysis confirmed the 
fact that the gathered data showed not statistical difference between any of the five experimental groups.  
The results, therefore show no difference in mutant and normal DMPK transcripts between the cells 
containing either type of PTM and the three controls.  
The lack of difference between the groups can be interpreted in two ways: either no trans-splicing repair 
of DMPK occurred within the model or the trans-splicing repair of DMPK was too minimal to detect.  
Taking the first interpretation to be true, one is left to answer why no SMaRT repair occurred.  Some 
possible scenarios include: 1) the PTM never reached the nucleus 2) the PTM never reached the target 
transcription factory.   
The possibility of the PTM failing to reach the nucleus the least likely cause.  Both lipofectamine, the 
transfection regent used for introduction of the PTM into the cell, and the pc3.1DNA vector used to 
transport the PTM sequence are standard laboratory tools.  Because of these facts, the chance that the 
PTM plasmid failed to reach the nucleus is fairly slim and does not provide a reasonable account of the 
results. All the same, the possibility that some contaminant may have destroyed the PTM culture or that 
the PTMs were degraded in the process of storage is always a lingering possibility, albeit unlikely.  
A more worthwhile postulate is that no trans-splicing occurred due to failure of the PTM to be included 
in the transcription factory containing the DMPK gene.  The failing of PTMs to find their proper position 
in the transcription factory has been discussed before.  In this case, it is not likely to be wholly due to 
faulty binding domain.  PTMs of the same construction as the experimental antisense PTMs have been 
used successfully in the past.   If the problem was due to the binding domain, it would be expected that 
at least a small level of splicing would have been observed in the culture receiving the DMPK AS 
plasmid.  However, neither experimental culture showed splicing.  This seems to indicate that the 
targeting provided by the binding domain did not play a role in where the experimental PTMs were 
positioned within the nucleus.   
 In this experiment, a fairly high concentration of plasmids was used, 1.2 micrograms per 600,000 cells. 
This over dosage of plasmids had been intentional to ensure that PTMs would successfully reach all of 
the cells.  However, how the number of plasmids affects the sorting processes of the nucleus is not well 
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known.  It is possible that only plasmids under a certain concentration will be integrated into endogenous 
transcription factories.  If that concentration is exceeded, it is possible that the nuclear mechanisms 
instead associate the plasmids with each other resulting in the creation of an artificial transcription 
factory.  The high quantity of PTM plasmids within the nucleus of the experimental cultures may have 
resulted in them being sequestered into specialized plasmid foci, rather than integrating them into the 
DMPK transcription factory.  The result of such would be that no splicing would occur and no change 
would be seen in the number of mutant DMPK transcripts when compared to their normal companions, 
a result that matches the experimental data.      
It is additionally worth considering the possibility that trans-splicing of mutant DMPK did occur, but at 
low enough levels that the event was undetected.   This points to a slight disadvantage of the current 
method of data evaluation.  Because DMPK transcripts are evaluated by length, the presence of the 
normal allele prevents direct detection of trans-spliced products. The failure to differentiate between the 
two transcripts is a drawback that should be remedied in future investigations and is required for 
understanding what errors are occurring within the experiment. 
Though the results of this experiment failed to address the hypothesis and to determine whether the 
efficiency SMaRT technology could be improved by a use of a sense binding domain in the PTM, it has 
provided valuable ground work for future investigations.  Further work should focus on two aspects: 
improving differentiation between normal and trans-spliced DMPK transcripts and evaluation of the 
effects of plasmid density upon PTM incorporation and segregation within the nucleus.   
One method that would allow distinction to be made between normal and repaired DMPK transcripts 
would be to include a unique sequence within the coding region of the PTM which would allow the 
isolated detection of trans-spliced products.  This has the drawback of potentially requiring two PCR 
reactions to be run, one looking at endogenous transcripts and the other at repaired products.  A different 
approach could be prepare the PTM to contain a repeat sequence that was of intermediate length, perhaps 
containing 50-100 additional repeats.  The same technique of analysis presented in this experiment might 
be used.  The result would be that instead of two bands as observed, three bands should occur: the high 
band for the toxic transcripts, the low band for the endogenous normal transcripts, and an additional 
third band somewhere between the two for trans-spliced products.  The advantages of such an approach 
would be that it would allow a direct visualization of all types of DMPK mRNA present within the cell.  
This method would, however, necessitate that the separation of the three bands to be clear enough for 
analysis, something that was slightly challenging even when working with two expected bands.  
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Additionally, future studies should use lower concentrations of plasmids when transfecting cells. To 
determine whether the splicing is affected by concentration, experiments should be conducted using 
antisense binding domain plasmids since these have prior experimental evidence of trans-splicing repair.  
As the concentration of the PTMs is decreased, the trans-splicing rates should increase.  This will allow 
the determination of the most favorable plasmid concentration to be used for further experimentation.  
Once the plasmid concentration has been optimized, it will be possible to examine the effects on 
efficiency that are caused by the use of PTMs with sense binding domain. 
SMaRT technology holds great promise in the field of gene therapy, specifically in its potential for 
correcting RNA toxicity diseases such as DM1.   Demonstrating its potential, however, still requires 
much further investigation, particularly in improving the efficiency of the artificial PTM molecules.    
Though this study was unable to provide proof of concept for the use of sense binding domains, it has 
been an integral part of the future studies that must be done in order to make SMaRT repair of DM1 a 
reality.  This research has shown the direction that future experimentation ought to take and has set the 
foundation for further investigation in binding domain improvement.   
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